{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:52:50Z","timestamp":1744203170045},"reference-count":32,"publisher":"Pan American Health Organization","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,8]]},"abstract":"<p><bold>Objetivo.<\/bold> <italic>Estimar as taxas de resist\u00eancia \u00e0s drogas entre casos de tuberculose pulmonar (TBP) para o estado de Mato Grosso do Sul, Brasil, e especificamente para a regi\u00e3o da fronteira com Paraguai e Bol\u00edvia, al\u00e9m de identificar fatores de risco associados.<\/italic><\/p>\n<p><bold>M\u00e9todos.<\/bold> <italic>O presente estudo epidemiol\u00f3gico, transversal, enfocou os casos de TBP registrados de janeiro de 2007 a dezembro de 2010 no Sistema de Informa\u00e7\u00e3o de Agravos de Notifica\u00e7\u00e3o da Secretaria de Estado de Sa\u00fade com resultados do teste de suscetibilidade a rifampicina, isoniazida, etambutol e estreptomicina. Definiram-se como vari\u00e1veis dependentes o desenvolvimento de resist\u00eancia a uma \u00fanica droga e a qualquer combina\u00e7\u00e3o de drogas. As vari\u00e1veis independentes foram ser caso novo ou tratado, resid\u00eancia em regi\u00e3o de fronteira ou outra regi\u00e3o, presen\u00e7a ou aus\u00eancia de diabetes e hist\u00f3ria de alcoolismo.<\/italic><\/p>\n<p><bold>Resultados.<\/bold> <italic>Foram identificados 789 casos de TBP com teste de suscetibilidade. As caracter\u00edsticas associadas \u00e0 resist\u00eancia foram: caso tratado (<\/italic>P<italic>=0,0001), regi\u00e3o de fronteira (<\/italic>P<italic>=0,0142), alcoolismo (<\/italic>P<italic>=0,0451) e diabetes (<\/italic>P<italic>=0,0708). As taxas de resist\u00eancia combinada, prim\u00e1ria e adquirida no estado foram de 16,3%, 10,6% e 39,0%, e na fronteira, de 22,3%, 19,2% e 37,5%. As taxas de resist\u00eancia a m\u00faltiplas drogas combinada, prim\u00e1ria e adquirida no estado foram de 1,8%, 0,6% e 6,3%, e na fronteira, de 3,1%, 1,2% e 12,5%.<\/italic><\/p>\n<p><bold>Conclus\u00f5es.<\/bold> <italic>O estado deve, na regi\u00e3o de fronteira, realizar cultura em todos os sintom\u00e1ticos respirat\u00f3rios, investigar o padr\u00e3o de resist\u00eancia nos casos confirmados, adotar o tratamento diretamente observado nos casos de TBP e desencadear a\u00e7\u00f5es de sa\u00fade conjuntas com os pa\u00edses fronteiri\u00e7os. Em todo o estado, \u00e9 necess\u00e1rio monitorar os n\u00edveis de resist\u00eancia adquirida, ampliar a investiga\u00e7\u00e3o de resist\u00eancia para todos os casos tratados e adotar o tratamento diretamente observado prioritariamente entre pacientes com alcoolismo e diabetes.<\/italic><\/p>","DOI":"10.26633\/rpsp.2017.9","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T10:46:27Z","timestamp":1563792387000},"page":"1","source":"Crossref","is-referenced-by-count":4,"title":["Resist\u00eancia \u00e0s drogas antituberculose na fronteira do Brasil com Paraguai e Bol\u00edvia"],"prefix":"10.26633","volume":"41","author":[{"given":"Marli","family":"Marques","sequence":"first","affiliation":[{"name":"Universidade Federal de Mato Grosso do Sul, Programa de P\u00f3s-Gradua\u00e7\u00e3o em Doen\u00e7as Infecciosas e Parasit\u00e1rias, Campo Grande (MS), Brasil."},{"name":"marli.marques2008@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice Atsuko","family":"Totumi Cunha","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio Central de Sa\u00fade P\u00fablica de Mato Grosso do Sul, Campo Grande (MS), Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria do Socorro Nantua","family":"Evangelista","sequence":"additional","affiliation":[{"name":"Universidade de Bras\u00edlia, Programa de P\u00f3s-Gradua\u00e7\u00e3o da Faculdade de Ci\u00eancias da Sa\u00fade e de Enfermagem, Bras\u00edlia (DF), Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Cesar","family":"Basta","sequence":"additional","affiliation":[{"name":"Escola Nacional de Sa\u00fade P\u00fablica (ENSP), Funda\u00e7\u00e3o Oswaldo Cruz (FIOCRUZ), Rio de Janeiro (RJ), Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria Campos","family":"Marques","sequence":"additional","affiliation":[{"name":"Universidade Anhanguera\/Uniderp, Faculdade de Medicina, Campo Grande (MS), Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Croda","sequence":"additional","affiliation":[{"name":"Universidade Federal da Grande Dourados, Programa de P\u00f3s-Gradua\u00e7\u00e3o da Faculdade de Ci\u00eancias da Sa\u00fade, Dourados (MS), Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia Maria","family":"Oliveira de Andrade","sequence":"additional","affiliation":[{"name":"Universidade Federal de Mato Grosso do Sul, Programa de P\u00f3s-Gradua\u00e7\u00e3o em Doen\u00e7as Infecciosas e Parasit\u00e1rias, Campo Grande (MS), Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11167","reference":[{"key":"ref1","unstructured":"1. Lehmann J. Twenty years afterward. Historical notes on the discovery of the antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical trials. Am Rev Respir Dis. 1964;90: 953\u20136."},{"key":"ref2","unstructured":"2. Long ER, Ferebee SH. A controlled investigation of streptomycin treatment in pulmonary tuberculosis. Public Health Resp. 1950;65(44):1421\u201351."},{"key":"ref3","unstructured":"3. Pablos-Mendes A, Raviglione MC, Laszlo A, Binkin N, Rieder HI, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994\u20131997. World Health Organization \u2013 International Union against Tuberculosis and Lung Disease Working Group on Anti-tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998;338(23):1641\u20139."},{"key":"ref4","unstructured":"4. World Health Organization. The WHO\/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Antituberculosis drug resistance in the world. Genebra: WHO; 2008 [Report no. 4. WHO\/HTM\/TB\/2008.394]."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Goble M, Iseman MD, Masden LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527\u201332.","DOI":"10.1056\/NEJM199302253280802"},{"key":"ref6","unstructured":"6. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis. 2010;14(4):382\u201390."},{"key":"ref7","unstructured":"7. Pablo-M\u00e9ndez A, Gowda DK, Frieden TR. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull World Health Organ. 2002;80(6):489\u2013500."},{"key":"ref8","unstructured":"8. World Health Organization. Multidrug and extensively drug-resistant TB (M\/XDR-TB): 2010 global report on surveillance and response. Dispon\u00edvel em: http:\/\/apps.who.int\/iris\/bitstream\/10665\/44286\/1\/9789241599191_eng.pdf Acessado em 2 de julho de 2015."},{"key":"ref9","unstructured":"9. World Health Organization. Global tuberculosis report 2013. Genebra: WHO; 2013 [WHO\/HTM\/TB\/2013.11]."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007\u20132010. Bull World Health Organ. 2012;90(2):111\u20139.","DOI":"10.2471\/BLT.11.092585"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Kritski LA. Emerg\u00eancia de tuberculose resistente: renovado desafio. J Bras Pneumol. 2010;36(2):157\u20138.","DOI":"10.1590\/S1806-37132010000200001"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Marques M, Cunha EA, Ruffino-Netto A, Andrade SMO. Perfil de resist\u00eancia de Mycobacterium tuberculosis no estado de Mato Grosso do Sul, 2000\u20132006. J Bras Pneumol. 2010;36(2):224\u201331.","DOI":"10.1590\/S1806-37132010000200011"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Marques M, Ruffino-Netto A, Marques AMC, Andrade SMO, Silva BAK, Pontes ERJC. Magnitude da tuberculose pulmonar na popula\u00e7\u00e3o fronteiri\u00e7a de Mato Grosso do Sul (Brasil), Paraguai e Bol\u00edvia. Cad Saude Publica. 2014;30(12):2631\u201342.","DOI":"10.1590\/0102-311x00191513"},{"key":"ref14","unstructured":"14. Brasil. Instituto Brasileiro de Geografia e Estat\u00edstica. Dispon\u00edvel em: http:\/\/www.ibge.gov.br\/home\/ Acessado em 10 de julho de 2012."},{"key":"ref15","unstructured":"15. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis. 1965;92(5):687\u2013703."},{"key":"ref16","unstructured":"16. Brasil. Resolu\u00e7\u00e3o 466\/12 do Conselho Nacional de Sa\u00fade. Dispon\u00edvel em: http:\/\/conselho.saude.gov.br\/resolucoes\/2012\/Reso466.pdf Acessado em outubro de 2016."},{"key":"ref17","unstructured":"17. Cunha EAT, Marques M, Leite CQF, Junqueira CT, Ar\u00e3o CAB, Costa IP. Contribui\u00e7\u00e3o do LACEN-MS no diagn\u00f3stico da tuberculose e da resist\u00eancia \u00e0s drogas antituberculosas em Mato Grosso do Sul. Rev Bras Anal Clinic. 2009;41(3):191\u20136."},{"key":"ref18","unstructured":"18. Chiang C-Y. Basic concepts and definitions of drug resistance in tuberculosis. Em: Caminero JA. Guidelines for clinical and operational management of drug-resistant tuberculosis. Paris: International Union Against Tuberculosis and Lung Disease; 2013. Pp. 13\u201325. Dispon\u00edvel em: http:\/\/www.theunion.org\/what-we-do\/publications\/technical\/english\/mdr-tbguide_6-19-13_web.pdf Acessado em 2 de julho de 2015."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Basta PC, Marques M, Oliveira RL, Cunha EAT, Resendes APC, Souza-Santos R. Desigualdades sociais e tuberculose: an\u00e1lise segundo ra\u00e7a\/cor, Mato Grosso do Sul. Rev Saude Publica. 2013;47(5):854\u201364.","DOI":"10.1590\/S0034-8910.2013047004628"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Garrido MS, Ramasawmy R, Perez-Porcuna TM, Zaranza E, Talhari AC, Martinez-Espinosa MF, et al. Primary drug resistance among pulmonary treatment-na\u00efve tuberculosis patients in Amazonas State, Brazil. Int J Tuberc Lung Dis. 2014;18(5):559\u201363.","DOI":"10.5588\/ijtld.13.0191"},{"key":"ref21","unstructured":"21. Brasil, Minist\u00e9rio da Sa\u00fade. Manual de Recomenda\u00e7\u00f5es para o controle da tuberculose no Brasil. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2011."},{"key":"ref22","unstructured":"22. Fi\u00faza de Mello FA, Affiune JB, Ribeiro LHG, Felice EA, Castelo A. Resist\u00eancia prim\u00e1ria do M. tuberculosis num servi\u00e7o ambulatorial de refer\u00eancia em S\u00e3o Paulo: evolu\u00e7\u00e3o por tr\u00eas d\u00e9cadas e compara\u00e7\u00e3o com outros estudos nacionais. J Pneumol. 1996;22(1):3\u20138."},{"key":"ref23","unstructured":"23. Belo EN, Orellana JDY, Levino A, Basta PC. Tuberculose nos munic\u00edpios amazonenses da fronteira Brasil-Col\u00f4mbia-Peru-Venezuela: situa\u00e7\u00e3o epidemiol\u00f3gica e fatores associados ao abandono. Rev Panam Salud Publica. 2013;34(5):321\u20139."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24. Rios DPG, Malacarne J, Alves LCC, Sant\u2019Anna CC, Camacho LAB, Basta PC. Tuberculose em ind\u00edgenas da Amaz\u00f4nia brasileira: estudo epidemiol\u00f3gico na regi\u00e3o do Alto Rio Negro. Rev Panam Salud Publica. 2013;33(1):22\u20139.","DOI":"10.1590\/S1020-49892013000100004"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, L\u00f6nnroth K, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009;9:450.","DOI":"10.1186\/1471-2458-9-450"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Reis-Santos B, Gomes T, Locatelli R, de Oliveira ER, Sanchez MN, Horta BL, et al. Treatment outcomes in tuberculosis patients with diabetes: A polytomous analysis using Brazilian surveillance system. PLoS ONE. 2014;9(7):e100082.","DOI":"10.1371\/journal.pone.0100082"},{"key":"ref27","unstructured":"27. World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes. Genebra: WHO; 2011."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. Gomes M, Correia A, Mendon\u00e7a D, Duarte R. Risk factors for drug-resistant tuberculosis. J Tuberculosis Res. 2014;2(3):111\u20138.","DOI":"10.4236\/jtr.2014.23014"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29. Dooley K, Chaisson R. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737\u201346.","DOI":"10.1016\/S1473-3099(09)70282-8"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Rawat J, Sindhwani G, Biswas D. Effect of age on presentation with diabetes: Comparison of nondiabetic patients with new smear-positive pulmonary tuberculosis patients. Lung India. 2011;28(3):187\u201390.","DOI":"10.4103\/0970-2113.83975"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"31. Chang JT, Dou HY, Yen CL, Wu YH, Huang RM, Lin HJ, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Form Med Assoc. 2011;110(6):372\u201381.","DOI":"10.1016\/S0929-6646(11)60055-7"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"32. Harries AD, Lin Y, Satyanarayana S, L\u00f6nnroth K, Li L, Wilson N, et al. The looming epidemic of diabetes associated tuberculosis: learning lessons from HIV-associated tuberculosis. Int J Tuberc Lung Dis. 2011;15(11):1436\u201344.","DOI":"10.5588\/ijtld.11.0503"}],"container-title":["Revista Panamericana de Salud P\u00fablica"],"original-title":[],"language":"es","link":[{"URL":"http:\/\/iris.paho.org\/xmlui\/bitstream\/handle\/123456789\/33839\/v41a92017.pdf?sequence=1&isAllowed=y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T14:22:36Z","timestamp":1572618156000},"score":1,"resource":{"primary":{"URL":"http:\/\/iris.paho.org\/xmlui\/handle\/123456789\/33839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,8]]},"references-count":32,"alternative-id":["RPSP.2017.9"],"URL":"https:\/\/doi.org\/10.26633\/rpsp.2017.9","relation":{},"ISSN":["1020-4989","1680-5348"],"issn-type":[{"value":"1020-4989","type":"print"},{"value":"1680-5348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,8]]}}}